Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GCT - NK cell therapy - Glycostem

Drug Profile

GCT - NK cell therapy - Glycostem

Alternative Names: Allogeneic UCB-NK cells; GCT NK cells; Natural killer cells - Glycostem; NK cells - Glycostem; oNKord®; UCB-NK cells

Latest Information Update: 08 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glycostem
  • Class Cell therapies; Natural killer cell therapies
  • Mechanism of Action Immunostimulants; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia
  • Preclinical Haematological malignancies; Multiple myeloma; Solid tumours

Most Recent Events

  • 28 Mar 2019 Glycostem plans a pivotal clinical trial in the second half of 2019
  • 08 Jun 2018 Phase-I development in Acute-myeloid-leukaemia (In the elderly, Second-line therapy or greater) and Preclinical development in Haematological-malignancies, Multiple-myeloma and Solid-tumours is ongoing in Netherlands (IV) (9242625; Glycostem website)
  • 28 May 2018 Radboud University and KWF plan the phase I INTRO trial for Ovarian carcinoma, Fallopian tube carcinoma and Peritoneal carcinoma (Recurrent) in Netherlands (Intraperitoneal, Infusion) (NCT03539406)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top